Earn a maximum of 3 AMA PRA Category 1 Credit(s)™ by participating in both the Roundtable Webcast and Monograph on Acute Decompensated Heart Failure today!
Roundtable Webcast: Congestion
in
Acute
Decompensated Heart Failure: A Case Based Discussion
Release date: December 31, 2007
Available for credit through: December 31, 2008
Program Description
Congestion in Acute Decompensated Heart Failure: A Case Based Discussion is presented by Dr. Clyde Yancy, the Medical Director of the Baylor Heart and Vascular Institute at Baylor University Medical Center, Dallas, Texas and Dr. Mihai Gheorghiade, Professor of Medicine and Surgery and Associate Chief of the Division of Cardiology at the Feinberg School of Medicine at Northwestern University, Chicago, Illinois.
This activity reviews the definition, demographics, and risks of acute decompensated heart failure. Our expert faculty will discuss the strengths, limitations and concerns of standard therapies such as diuretics, vasodilators, inotropes, and natriuretic peptides. The faculty will also discuss emerging therapies including ultrafiltration, adenosine antagonists, and vasopressin receptor antagonists. This activity aims to give cardiologists and other cardiac care givers a good understanding of how to optimize medical therapy for their patients with acute decompensated heart failure, with an emphasis on relieving symptoms.
Accreditation
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
ArcMesa Educators designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Educational Objectives
Upon completion of this activity, participants should be able to:
Discuss the demographics of ADHF
Describe predictors of mortality in patients with ADHF, outcomes, and a risk assessment algorithm
Discuss the guideline-recommended management of ADHF, including pharmacologic and nonpharmacologic treatment
Elaborate on the results of trials of treatments currently in late-stage development for the treatment of ADHF
Target Audience
This activity was developed for cardiologists and other physicians involved in the management of heart failure.
Monograph: Update on
the Management of
Acute Decompensated Heart Failure
Release
date: April 30, 2008
Available
for credit through: April 30, 2009
Program
Description
Heart failure (HF) is a
common cardiac condition whose incidence and prevalence is expected to increase
as the population ages. When HF patients experience a worsening of their signs
and symptoms, there is an urgent need for treatment. This monograph describes
the characteristics of patients with acute decompensated HF (ADHF) and a risk
stratification algorithm for determining patient risk of increased length of
stay and in-hospital mortality. Predictors of mortality in ADHF, including
congestion, worsening renal function, elevated brain natriuretic peptide,
hyponatremia, and blood pressure are examined in detail. Goals of treatment and
guideline-recommended management strategies, including the use of diuretics,
sodium and fluid restriction, ultrafiltration, vasodilator therapy, and
inotropic agents are outlined.
Currently available
treatment strategies for ADHF do not address the underlying pathophysiology. For
this reason, the search for better treatment options continues. Therapies in
late-stage development for the treatment of patients with ADHF are described in
this monograph. Cardiologist and other healthcare professionals who care for patients
with ADHF will find this information useful in optimizing the care of these
patients.
Accreditation:
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
ArcMesa Educators designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Educational
Objectives Upon completion of
this activity, participants should be able to:
Discuss the demographics
of ADHF
Describe predictors of
mortality in patients with ADHF, outcomes, and a risk assessment algorithm
Discuss the
guideline-recommended management of ADHF, including pharmacologic and nonpharmacologic
treatment
Elaborate on the results
of trials of treatments currently in late-stage development for the treatment
of ADHF
Target
Audience
This activity was developed
for cardiologists and other physicians involved in the management of heart
failure.
Disclosure Policy
It is the policy of ArcMesa Educators to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of ArcMesa Educators.
Faculty Disclosure Declarations Mihai Gheorghiade, MD, FACC Grants/Research Support - National Institutes of Health, Otsuka, Sigma Tau, Merck & Company, SCIOS Inc Consultant - GlaxoSmithKline, PDL, Errekappa Terapeutici, Medtronic, Debbio Pharm Honoraria – Abbott, AstraZeneca, GlaxoSmithKine, Medtronic, Otsuka, Protein Design Labs, SCIOS Inc, Sigma Tau Editorial Board Involvement – Heart Failure Reviews, American Journal of Therapeutics (Associate Editor), American Heart Journal, Current cardiology Reviews, Expert Review of Cardiovascular Therapy, Heart Disease: A Journal of Cardiovascular Medicine, Heart International, The American Journal of Cardiology, The Journal of Heart Disease, The Journal of Heart Failure, Journal of Cardiac Failure, Journal of the American College of Cardiology, archives for Chest Disease (Associate Editor), Italian Heart Journal, Acute Cardiac Care Journal (Associate Editor)
Clyde W. Yancy, MD, FACC, FAHA, FACP Consultant - GlaxoSmithKline, SCIOS, Inc., NitroMed, Medtronic, AstraZeneca, Otsuka Grants/Research Support - GlaxoSmithKline, SCIOS, Inc., NitroMed, Medtronic Speaker's Bureau - GlaxoSmithKline, Novartis
Terry Ann Glauser, MD, MPH - Medical Writer Independent Contractor – Johnson & Johnson
Staff Disclosure Declarations
The employees of ArcMesa Educators have nothing to disclose relative to this activity.
How to Receive Credit
After reviewing the entire activity, credits will be issued upon successful completion of the exam and submission of the activity evaluation form. Certificate of completion will be available to print from your history page.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
Mihai Gheorghiade, MD, FACC Professor of Medicine and Surgery
Associate Chief, Division of Cardiology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Clyde W. Yancy, MD, FACC, FAHA, FACP Medical Director
Baylor Heart and Vascular Institute
Baylor University Medical Center
Dallas, Texas
